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A case of thyrotoxic periodic paralysis as initial 
manifestation of Graves' disease in a 16-year-old 
Korean adolescent
Case report
Thyrotoxic periodic paralysis (TPP) is a rare complication of hyperthyroidism, with 
recurrent muscle paralysis and hypokalemia that are caused by an intracellular 
shift of potassium. TPP is relatively common in Asian males, but is extremely rare in 
children and adolescents, even for those of Asian descent. We describe a 16-year-old 
Korean adolescent presenting with a two-week history of episodic leg weakness in 
the morning. He showed sinus tachycardia, lower leg weakness, and hypokalemia. 
Thyroid function test showed hyperthyroidism, and thyroid ultrasonography 
revealed a diffuse enlarged thyroid with increased vascularity, consistent with 
Graves’ disease. He was treated with β-adrenergic blocker and antithyroid drugs. He 
has been symptom free for one year, as his hyperthyroidism has been controlled 
well with antithyroid drugs. TPP should be considered in children and adolescents 
with acute paralysis of the lower extremities and hypokalemia. 
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Thyrotoxic periodic paralysis (TPP) consists of episodes of muscle paralysis due to the 
hypokalemia that is associated with hyperthyroidism1). Even though TPP mainly affects Asian 
populations with an incidence of approximately only 2% in hyperthyroidism patients2), it is a 
very rare disease in children and adolescents in Asian as well as other ethnic groups. Paralysis 
of TPP is characterized by acute, reversible attacks of flaccid paralysis affecting the proximal 
muscles more severely than the distal muscles3). The extent of paralysis varies from mild 
weakness to complete flaccid paralysis, and although spontaneous resolution of the paralysis 
occurs in from a few hours to two days, cases of fatal ventricular arrhythmia4) and respiratory 
failure have been reported. Therefore, early recognition and prompt treatment is essential for 
avoiding such fatal complications. However, the diagnosis of TPP in children is challenging, 
because it is very rare in children and adolescents, and paralysis is occasionally the first and 
sole signs of TPP. We report on a Korean adolescent who presented with TPP as the initial 
manifestation of Graves’ disease.
Case report
A 16-year-old Korean male presented with two episodes of lower leg paralysis in the 
morning for two weeks. The first episode was a sudden onset of complete paralysis below 
distal thigh, and he had no other symptoms except leg paralysis. At a local clinic, physical 
examination revealed symmetric hyporeflexia in both lower extremities. Laboratory analysis 
revealed mild hypokalemia as below: Na+, 146 mmol/L; K+, 2.7 mmol/L; Cl−, 110 mmol/L; 
tCO2, 25 mmol/L without abnormality of blood gas analysis. Electrocardiogram showed only 
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sinus tachycardia without atrioventricular block or prominent 
U wave. However, further evaluation for hypokalemia was not 
taken, even though there was a suggestion of hypokalemic 
paralysis, and the patient was just advised to eat an adequate 
dietary supplement of  potassium rich food without any 
medication by the local clinic. After two weeks, a second episode 
of leg weakness occurred after morning meal. The muscle 
weakness was initially subtle but progressed in paralysis below 
knee and lasted for 6 hours. Thus, he was referred to our hospital. 
However, the patient visited our clinic the next day, when the 
paralysis had already subsided.
There was no past history or family history of neuromuscular 
disease and endocrinologic disease, except for his aunt’s 
hypothyroidism. His appearance was reasonably healthy. 
His height was 168 cm, his weight was 60 kg, and his body 
mass index was 21.2 kg/m2. His blood pressure was 110/80 
mmHg, his respiratory rate was 18 breaths/min, and his body 
temperature was 36.8℃. He had mild tachycardia with a 
heart rate of 100–110 beats/min,, but he had no palpitations. 
Neurological examination findings, including deep tendon 
reflex and cerebellar function test, were normal. The laboratory 
findings showed normal complete blood cell counts, normal 
electrolytes as below: Na+, 140 mmol/L; K+, 4.4 mmol/L; Cl−, 
104 mmol/L; tCO2, 24 mmol/L. The laboratory findings also 
showed his normal liver, kidney and cardiac functions. His 
urine K+ excretion rate was normally low as 0.96 of urine K+/
Cr ratio (range, 0–2). There were no abnormal laboratory 
findings to suggest adrenal hormone excess or primary 
hyperaldosteronism: adrenocorticotropic hormone, 40.11 pg/
mL (range, 3.5–13.2 pg/mL); cortisol, 8.7 µg/dL (range, 5.0–23.0 
µg/dL); 17 hydroxyprogesterone, 2.68 ng/mL (range, 0.6–3.42 
ng/mL); aldosterone, 180.29 pg/mL (range, 38.9–306.8 pg/mL); 
renin, 6.13 ng/mL/hr (range, 1.31–3.95 ng/mL/hr); epinephrine, 
0.030 ng/mL (range, 0–0.30 ng/mL); norepinephrine, 0.087 ng/
mL (range, 0–0.80 ng/mL). Thyroid function test (TFT) revealed 
a hyperthyroidism: serum free thyroxine (fT4), 2.10 ng/dL 
(range, 0.70–1.48 ng/dL); triiodothyronine (T3), 2.95 ng/mL 
(range, 0.58–1.59 ng/mL); thyroid-stimulating hormone (TSH), 
<0.025 mU/L (range, 0.35–4.94 mU/L). Thus, he was diagnosed 
as having hypokalemic paralysis due to hyperthyroidim. 
Serum TSH receptor antibodies were high at 6.05 IU/L (range, 
0–1.75 IU/L), thyroid stimulating antibody was positive, and 
Table 1. Thyroid function test and electrolytes during follow-up
Variable 1st Paralysis At diagnosis2nd paralysis 2 Weeks 1 Months 2 Months 4 Months 6 Months 9 Months
Free T4 (ng/dL) N/A 2.10 2.97 2.14 1.57 1.20 1.31 1.07
T3 (ng/mL) N/A 2.95 >8.00 3.57 1.82 1.23 1.24 1.14
TSH (uIU/mL) N/A <0.025 <0.025 <0.025 <0.025 <0.025 <0.025 0.230
Na+ (mmol/L) 146 139 140 143 142 140 140 142
K+ (mmol/L) 2.7 4.6 4.4 4.2 3.8 4.3 4.1 4.2
Cl- (mmol/L) 110 102 104 106 103 105 104 105
tCO2 (mmol/L) 25 27 24 24 27 24 26 25
Muscle weakness Lower leg paralysis
  for 12 hr
Lower leg paralysis
  for 6 hr
None None None None None None
Methimazole None 5 mg q.d. 10 mg b.i.d 10 mg b.i.d 10 mg b.i.d 10 mg b.i.d 7.5 mg b.i.d 7.5 mg b.i.d
Propranolol None 10 mg t.i.d  10 mg t.i.d 10 mg t.i.d  Discontinued
T4, thyroxine; T3, triiodothyronine; N/A, not available; TSH, thyroid-stimulating hormone; q.d., once a day; b.i.d., twice a day; t.i.d., three 
times a day. 
Table 2. Characteristics of previously reported adolescent TPP patients









Patient 1 M 16 Chinese Graves’ disease 1.64 4.04 <0.03 2.0 Propranolol + MMI 
  —> RI
5





Patient 3 F 14 Korean Graves’ disease 3.80 1.83 <0.03 2.3 Propranolol + MMI 7
Patient 4 M 16 Korean Graves’ disease 1.87 1.80 0.09 2.5 MMI Three recurrent 
  TPP despite 
  treatmentb) 
8
Patient 5 M 16 Korean Graves’ disease 2.10 2.95 <0.03 2.7C) Propranolol + MMI  
TPP, thyrotoxic periodic paralysis; T4, thyroxine; T3, triiodothyronine; TSH, thyroid-stimulating hormone; MMI, methimazole; RI, radioactive 
iodine 
a)Rebound hyperkalemia was occurred in patient 2 after intravenous potassium replacement. The potassium level was high as 7 mmol/L, 
and was normalized without any complication. b)Patient 4 experienced three times of TPP during treatment with methimazole. c)Patient 5 
is presenting case in this article. The potassium level and thyroid function test of patient 5 was not examined simultaneously. 
171
Jung SY, et al. • TPP as initial symptom in adolescent with Graves’ disease
www.e-apem.org
thyroid ultrasonography revealed diffuse enlarged thyroid 
and increased vascularity. These findings were consistent 
with Graves’ disease as etiology of his hyperthyroidism. He 
was initially treated with lower dose of an antithyroid drug 
(methimazole 5 mg once daily) than usual, since his thyrotoxic 
symptoms and signs were absent, and his level of serum fT4 was 
not prominent. In addition, a β-adrenergic blocker (propranolol) 
was simultaneously used for preventing the paralysis. After two 
weeks, a follow-up TFT revealed aggravated hyperthyroidism, 
and he was treated with increased dose of antithyroid drugs. 
After two months, since his heart rate and blood pressure were 
stable and he had no symptoms of palpitations, β-blockers were 
discontinued successfully. No paralysis has occurred for one 
year, as hyperthyroidism can be well controlled with antithyroid 
drugs (Table 1).
Discussion
TPP is an uncommon complication of hyperthyroidism, 
with recurrent muscle paralysis and hypokalemia. 
Although TPP is rare, it is more prevalent in Asians than 
other ethnic groups. The incidence is approximately 2% in 
Asian hyperthyroidism patients2), and 0.1%–0.2% in North 
America3), but it has been increasingly reported in non-
Asians. Regarding age, TPP is most prevalent in 20–40 
years old, and is a very rare in children and adolescents. 
There are only few reported cases in pediatric patients5-8), 
even in Asian populations, and the exact incidence in 
the pediatric population has yet to be established. Our 
presenting case may be the third reported case of  a 
pediatric Korean TPP patient as far as we know. In review 
of previous reported pediatric TPP patients (Table 2), all of 
five were Asian patients with Graves’ disease. Only one was 
female patient which reflected the male predominance of 
TPP. 
The pathogenesis of TPP remains uncertain; however, 
it is well known that the hypokalemia in TPP is caused 
by the intracellular shift of potassium rather than pure 
potassium depletion in the body. The intracellular 
shift of potassium is primarily regulated with Na+-K+ 
adenosine triphosphatase (ATPase) pump activity in 
cell membranes, which exchanges Na+ (out of the cell) 
for K+ (into the cell). Therefore, the increased number 
or enhanced activity of Na+-K+ ATPase could induce 
hypokalemia leading to paralysis. Thyroid hormones, 
β-adrenergic catecholamine, and insulin are known 
activators of Na+-K+ ATPase. Thyroid hormones increase 
both the activity of Na+-K+ ATPase and the number 
of messenger RNA and proteins of Na+-K+ ATPase via 
transcriptional and posttranscriptional mechanisms, 
leading to an increased number of Na+-K+ ATPase9). 
Previous experimental studies have shown that the 
Na+-K+ ATPase activity is higher in thyrotoxic patients 
with TPP than in thyrotoxic patients without paralysis10), 
and the number of Na+-K+ ATPase is correlated with the 
serum thyroid levels11). In addition, excessive thyroid 
hormone is essential in TPP, since paralysis typically does 
not occur once the patient achieves euthyroid status. 
Catecholamines also increase the Na+-K+ ATPase activity 
via β-adrenergic receptors and through the activation of 
cyclic adeonosine monophosphate. It could explain why 
nonselective β-adrenergic blockers can abort or prevent 
paralytic attacks12), and why stressful conditions such as 
cold exposure, infection, emotional stress, and trauma can 
promote TPP. Furthermore, excessive thyroid hormone 
increases both number and activity of β-adrenergic 
receptors, which further increase the Na+-K+ ATPase 
activity, which becomes even worse in TPP. Na+-K+ ATPase 
activity is also increased by androgen13), therefore, TPP 
occurs predominantly in men, despite hyperthyroidism 
being more frequent in women. In the rest, insulin is 
another well-known activator of Na+-K+ ATPase, which 
would explain why a high carbohydrate meal could 
promote TPP.
Graves’ disease is the most common cause of TPP. 
Other causes of thyrotoxicosis include toxic nodular 
goiter, subacute thyroiditis, toxic adenoma, and TSH-
secreting pituitary tumor, which could induce paralysis14). 
Usually, a diagnosis of hyperthyroidism is not difficult, 
because of its typical symptoms and signs such as weight 
loss, heat intolerance, palpitations, and exophthalmos. 
However, in TPP patients, the clinical symptoms and 
signs of hyperthyroidism may be subtle, thus TPP is often 
overlooked in hypokalemic paralysis. A recent study in 
Taiwan revealed that only 17% of TPP patients have overt 
symptoms and signs of thyrtoxicosis15), and some reports 
have shown that paralysis is the initial and sole sign of 
thyrotoxicosis16) as in our case. Thus, recognizing the 
pattern of paralysis is important. Unfortunately, TPP is 
usually indistinguishable to other hypokalemic paralysis 
symptoms. The extent of paralysis is usually correlated 
with serum potassium level, although rare cases of 
normokalemic TPP had been reported17).
The onset of TPP is usually sudden; weakness begins in 
the lower proximal extremities, and can progress to flaccid 
quadriplegia. Deep tendon reflexes are usually decreased, 
but sensory function is usually spared. Most attacks occur 
during rests after exercise, not during exercise. It could 
be explained that exercise releases potassium from the 
skeletal muscles, but rest enhances the influx of potassium. 
These findings are consistent with other hypokalemic 
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paralysis as well as those in TPP. Typically, TPP patients 
do not have persistent neuromuscular symptoms between 
attacks, although these findings are not limited to TPP. 
Due to the subtlety of thyrotoxicosis and indistinguisha-
ble features of  paralysis from other etiologies, the 
differential diagnosis of TPP in hypokalemic paralysis is 
sometimes difficult. However, as Lin et al.18) had suggested, 
patients presenting with hypokalemic paralysis could be 
simply divided into two groups; hypokalemic paralysis 
due to the depletion of potassium in the body, or due to 
the intracellular shifting of K+. The urinary K+ excretion 
rate and the blood acid-base status may be helpful for a 
differential diagnosis. High K+ excretion and an abnormal 
acid-base suggest the mechanism is the depletion of 
potassium in the body. In these groups, metabolic alkalosis 
suggests that the etiology is renal tubular acidosis, toluene 
abuse, or diarrhea, while metabolic acidosis suggests 
mineralocorticoid excess, vomiting, use of diuretics, Gitel-
man’s syndrome, or Bartter’s syndrome as an etiology. 
While low urinary K+ excretion and normal acid base, as 
in our case, suggest that the mechanism is the intracellular 
shifting of K+ including TPP, as in familial periodic 
paralysis, barium poisoning, and idiopathic periodic 
paralysis. In brief, taking a detailed history, including 
family history, drug history, and laboratory examination 
including TFTs, blood gas analysis, and urinary analysis 
for potassium excretion rate are essential to the differential 
diagnosis. In the presented case, the patient showed only 
bilateral lower leg paralysis accompanying hypokalemia; 
thus, the etiology of hypokalemic paralysis should be 
evaluated, but it was overlooked at the local clinic. While 
he showed normal acid-base blood gas study, low urinary 
potassium excretion and hyperthyroidism, we could assess 
that his hypokalemia was induced by the intracellular 
shifting of potassium due to his hyperthyroidism. Further 
evaluation for hyperthyroidism revealed that he had 
Graves’ disease presenting with paralysis as his first and 
only manifestation.  
Treatment of TPP requires two steps, management of 
hypokalemia, and the maintenance of euthyroid status. 
Potassium replacement is necessary for the avoidance of 
fatal arrhythmia and for the rapid recovery from muscle 
weakness. However, hypokalemia is not caused by a total 
body depletion of potassium, and so cautious potassium 
replacement is essential to avoid rebound hyperkalemia on 
that account19). Besides potassium replacement, nonselec-
tive β-blockers are used for the prevention of recurrent 
paralysis based on the pathogenesis of hyperadrenergic 
activity during a thyrotoxic period. In review of preivous 
pediatric TPP, only one patient, who did not receive 
nonselective β-blockers, experienced recurrent paralysis. 
Recently, some cases of TPP were reversed with high-
dose oral propranolol (3 mg/kg) without potassium 
replacement to avoid the rebound hyperkalemia20). Regu-
lar potassium supplement is usually not required, as in 
our case. As paralysis does not occur once the patient 
has achieved euthyroid status, β-adrenergic blockers are 
usually used with other treatments during that period. 
Maintenance of euthyroidism is the definitive treatment 
of TPP. Antithyroid drugs are the mainstay of treatment 
of hyperthyroidism, although treatment should be indivi-
dualized for a patient. Four of five pediatric TPP cases 
including our case were treated with antithyroid drugs, 
while only one patient received radioactive iodine therapy 
after antithyroid drug treatment.
In conclusion, pediatricians should consider TPP as 
one of the differential diagnosis of muscle weakness or 
acute paralysis of the low extremities with hypokalemia 
in children and adolescents. TPP could be diagnosed by 
taking a detailed history and laboratory findings including 
blood gas analysis, urine potassium excretion ratio, and 
TFT.
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